CIZUMAB 100 MG

Clinical use of Bevacizumab is described in this record across Metastatic colorectal cancer; non-small cell lung cancer; ovarian/fallopian tube/peritoneal cancers; renal cell carcinoma; cervical cancer; glioblastoma and other label-specific indications. The medicine belongs to the vegf-a monoclonal antibody class and is categorized as Targeted Therapy; Monoclonal Antibody; VEGF Inhibitor. Binds VEGF-A and inhibits VEGF-mediated angiogenesis. Its antibody-based design gives the treatment a defined molecular target, so the relevant antigen or pathway and disease context guide its use. Colorectal; NSCLC; Ovarian; Cervical; Renal Cell Carcinoma; Glioblastoma are the associated tumor types listed in the database. Its regimen field includes FOLFOX + bevacizumab; FOLFIRI + bevacizumab; carboplatin/paclitaxel + bevacizumab; atezolizumab + bevacizumab; other disease-specific combinations. The range of combinations reflects disease-specific treatment design: the appropriate partner and treatment position depend on the malignancy and the indication being addressed. Molecular and disease-specific eligibility can therefore be more important than tumor location alone when the treatment is considered. When a molecular alteration, receptor profile, disease stage, or prior-treatment condition is explicitly included, it should not be separated from the indication itself. Those details help distinguish the medicine's intended role from broader statements about its drug class. Regulatory labeling and disease-specific guidelines should be reviewed for current clinical use.